Get the Stockscreener App
0.00
100.00%
-9.50
Poseida Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
See More
Previous Close:
$9.50
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$925.93M
Revenue:
$64.70M
Net Income/Loss:
$-123.43M
P/E Ratio:
0.00
EPS:
-1.38
Net Cash Flow:
$-95.23M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.67
Poseida Therapeutics Inc Stock (PSTX) Company Profile
Name
Poseida Therapeutics Inc
Sector
Industry
Phone
858-779-3100
Address
9390 TOWNE CENTRE DRIVE, SAN DIEGO
Compare PSTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTX
Poseida Therapeutics Inc
|
0.00 | 925.93M | 64.70M | -123.43M | -95.23M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.62 | 113.22B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
675.79 | 74.26B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
648.94 | 38.80B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.76 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.14 | 28.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-23 | Initiated | H.C. Wainwright | Buy |
| Jan-07-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Aug-04-20 | Initiated | BofA Securities | Buy |
| Aug-04-20 | Initiated | Piper Sandler | Overweight |
| Aug-04-20 | Initiated | William Blair | Outperform |
View All
Poseida Therapeutics Inc Stock (PSTX) Latest News
Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida - MSN
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Barclays PLC - Defense World
Roche to close $1.5B acquisition of Poseida Therapeutics - MSN
Jane Street Group LLC Has $296,000 Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics Completes Merger with Roche Holdings, Inc. and Blue Giant Acquisition Corp. - Defense World
Poseida Therapeutics acquired by Roche Holdings - Investing.com Australia
Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win (RHHBY) - Seeking Alpha
Major pharmaceutical company Roche buys cell and gene developer Poseida Therapeutics in $1.5 billion acquisition - BioProcess Insider
Poseida Therapeutics acquired by Roche Holdings By Investing.com - Investing.com South Africa
Roche completes tender offer for Poseida Therapeutics shares By Investing.com - Investing.com Canada
Roche Completes Biopharma Acquisition Worth Up To $1.5B - Law360
Poseida Therapeutics Undergoes Merger and Delisting Changes - TipRanks
Roche set to finalise $1.5bn Poseida Therapeutics takeover - Proactive Investors USA
Roche Finalizes Tender Offer for $1.5B Poseida Deal - TipRanks
Roche: Poseida acquisition nears completion -January 08, 2025 at 04:55 am EST - Marketscreener.com
Roche completes tender offer for Poseida Therapeutics shares - Investing.com India
Roche Completes Acquisition of Poseida TherapeuticsNews and Statistics - IndexBox, Inc.
Roche to close $1.5B acquisition of Poseida Therapeutics (OTCQX:RHHBY) - Seeking Alpha
Roche to complete acquisition of U.S. biopharma company Poseida - MSN
Roche to complete acquisition of U.S. biopharma company Poseida -January 08, 2025 at 01:35 am EST - Marketscreener.com
Roche purchases shares in tender offer for Poseida Therapeutics, Inc. - The Manila Times
Roche Completes Major Acquisition of Poseida Therapeutics with 66% Share Tender Success - StockTitan
Poseida Therapeutics (NASDAQ:PSTX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Poseida announces US waiting period expiration for deal with Roche - MLex
Geode Capital Management LLC Sells 5,438 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Bought by Barclays PLC - MarketBeat
Poseida Therapeutics (NASDAQ:PSTX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Poseida Therapeutics stock soars to 52-week high of $9.59 By Investing.com - Investing.com Australia
Poseida Therapeutics (NASDAQ:PSTX) Sets New 1-Year HighHere's Why - MarketBeat
Poseida Therapeutics stock soars to 52-week high of $9.59 - Investing.com
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Wellington Management Group LLP Reduces Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics (NASDAQ:PSTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Charles Schwab Investment Management Inc. Increases Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? - MSN
XTX Topco Ltd Increases Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics executive chairman sells $283,866 in stock By Investing.com - Investing.com Canada
Poseida Therapeutics executive chairman sells $283,866 in stock - Investing.com
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - The Eastern Progress Online
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - The Eastern Progress Online
Poseida Therapeutics' SWOT analysis: gene therapy firm's stock shows promise amid challenges - Investing.com Nigeria
Poseida Therapeutics' SWOT analysis: gene therapy firm's stock shows promise amid challenges By Investing.com - Investing.com South Africa
Poseida Therapeutics Inc Stock (PSTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
25.79%
2.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):